Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
US Army
Harvard Business School
Argus Health
Cipla
Healthtrust

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 10,214,590

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,214,590
Title:Inhibitors of endoglin activity for the treatment of fibrosis
Abstract: Endoglin has been identified to play a functional role as a regulator of TGF.beta.1 signaling, particular in TGF.beta.1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGF.beta.1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity.
Inventor(s): Kapur; Navin K. (Hanover, MA), Karas; Richard H. (Franklin, MA)
Assignee: Tufts Medical Center, Inc. (Boston, MA)
Application Number:15/022,663
Patent Claims:see list of patent claims

Details for Patent 10,214,590

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Sign Up Tufts Medical Center, Inc. (Boston, MA) 2033-09-20 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02 ➤ Sign Up Tufts Medical Center, Inc. (Boston, MA) 2033-09-20 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02 ➤ Sign Up Tufts Medical Center, Inc. (Boston, MA) 2033-09-20 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Argus Health
Accenture
Healthtrust
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.